| Tue 8 Dec 2009, 9:40 | | CMP - Cipla Medpro - Frost & Sullivan Award caps successful month for Cipla |
|
CMP
CMP
CMP - Cipla Medpro - Frost & Sullivan Award caps successful month for Cipla
Medpro South Africa Ltd
CIPLA MEDPRO SOUTH AFRICA LIMITED
(formerly Enaleni Pharmaceuticals Limited)
(Incorporated in the Republic of South Africa)
(Registration number 2002/018027/06)
(ISIN Number: ZAE000128179 & Share Code: CMP)
("Cipla Medpro" or "the company")
Frost & Sullivan Award caps successful month for Cipla Medpro South Africa Ltd
7 December 2009
Receiving the Frost & Sullivan `2009 South African Generic Pharmaceuticals
Company of the Year` award rounded off a successful November for pharmaceutical
company Cipla Medpro South Africa Limited.
News of the award came on the back of Cipla securing new first time government
tenders valued at nearly R100 million over two years, the company achieving year
to date sales of R1 billion as at the end of October 2009, and the finalization
of plans to bring 20 oncology drugs to market in the new year.
In the Frost & Sullivan Company of the Year Award, the following criteria were
used to benchmark Cipla Medpro`s performance against key competitors: growth
strategy and implementation, degree of innovation in business processes,
products and/or technologies and leadership in customer value and market
penetration.
"The company`s growth strategy is displayed in both its expanding geographic
footprint as well as the diversification of its unique product mix," noted Frost
& Sullivan Research Analyst Jolize Gerber. "The company is growing its South
African business by concentrating its efforts on establishing a stronger
presence in the local market across numerous therapeutic categories as well as
the fast-growing Over The Counter market and, despite adverse market conditions,
has enjoyed a solid recent performance in the past year."
The company has exhibited continued growth in its existing products and reveals
a strong pipeline of new products.
"Cipla Medpro creates and maintains strong brands by ensuring a robust pipeline
of novel, high potential products, and by providing ongoing promotions and
market support," adds Gerber. "These efforts support Cipla Medpro in growing
its market share in the South African market."
"We are extremely proud of the Frost & Sullivan Company of the Year Award which
acknowledges our efforts in making world class healthcare affordable in South
Africa, as well as the success of our growth strategy," said Jerome Smith, Cipla
Medpro CEO. "Cipla has been the fastest growing pharmaceutical company by value
for the past 3 years and that growth continues, as reflected in our year to date
sales figures of R1 billion."
In the recent round of state tenders, the bulk of the products awarded to Cipla
fell within the RT281 semi-solid dosage tender and include Over The Counter
(OTC) products such as Alkafizz, Gastrolyte and Acitop. The company also
obtained tenders under the RT297 for the supply of insulin needles and the RT290
oncology tender for the provision of cytoplastin. This is the first time the
company has been awarded these tenders.
Smith said approximately R50 million - R60 million of the products won on the
tenders would be manufactured locally at the group`s state of the art
manufacturing facility in Durban.
Smith also said the launch of the Cipla Medpro oncology division in the new year
is on track. The division will commence with 20 molecules targeting a host of
cancers, including breast, colon and lung, three of the leading causes of cancer
related deaths globally, as well as ovarian, and pancreatic cancers. Smith said
it`s likely that Cipla will boast the most comprehensive portfolio locally.
"The launch of our oncology division will augment our already comprehensive
portfolio of scientifically advanced medicines and bring us one step closer to
our goal of ensuring that world class medicines targeting many of today`s most
challenging disease categories are affordable to all South Africans," he said.
ends
Contact: Ros Walsh
Cipla Mepdro (Pty) Ltd
Tel: 031 275 9700
ros@ciplamedpro.co.za
Sponsor
Nedbank Capital
Date: 08/12/2009 09:40:05 Produced by the JSE SENS Department.
The SENS service is an information dissemination service administered by the
JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or
implicitly, represent, warrant or in any way guarantee the truth, accuracy or
completeness of the information published on SENS. The JSE, their officers,
employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature,
howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
